Jointown Pharmaceutical Group Co., Ltd.
Summary
Revenue :
000,000 M USD
Finance :
000,000 M USD
Earning Cap :
000,000 M USD
Invest :
000,000 M USD
R & D :
0000 People
Growth :
00% AGR
DIGDAL CAP
Overview
| General Introduction | Kyushu Tong Pharmaceutical Group Co., Ltd. (hereinafter referred to as the "Company" or "Kyushu Tong") is a technology-driven comprehensive service provider for the full chain pharmaceutical industry. The company is based in the major health industries such as pharmaceutical circulation, logistics services, and healthcare. Its main businesses include digital pharmaceutical distribution and supply chain business, general brand promotion business, pharmaceutical industry self-produced and OEM business, pharmaceutical retail and franchise business Six major areas include digital logistics and supply chain solutions, healthcare and technology value-added services. Kyushu Tong is the largest private pharmaceutical commercial enterprise in China, ranking fourth among Chinese pharmaceutical commercial enterprises. It is the first 5A logistics enterprise in the industry and the only enterprise to be rated as one of the top ten national intelligent warehousing and logistics demonstration bases. As a pioneer in the digitalization of the pharmaceutical industry, Kyushu Tong has taken the lead in transitioning and upgrading from traditional pharmaceutical distribution business to digitalization, platformization, and internetization, and has implemented a comprehensive service model of "pharmaceutical distribution+logistics distribution+product promotion", achieving good results. Relying on the advantages of full category procurement, full channel coverage, and full scenario services, Kyushu Tong has initially established a three-dimensional pharmaceutical supply chain service platform that combines online and offline services. By utilizing the Internet and digital tools, it aims to create a supply chain service platform that serves upstream production enterprises (F-end), downstream B-end customers (including medical institutions, pharmacies, clinics, fast-moving consumer goods stores, government procurement groups, etc.), and C-end users, And establish a coordinated and complementary B2B/B2C/O2O full scene digital service system in accordance with the F-B (Kyushu Tong) - B-C model. On the B-end, Kyushu Tong fully utilizes the advantages of "intelligence, digitization, and specialization" to transform the traditional terminal business model into a platform model that combines online and offline "self operated, joint venture, and local promotion", namely the "Pharmaceutical 99 Business Model". At the same time, relying on interconnected internal business systems, financial systems, and logistics systems, the company independently develops and continuously optimizes the Kyushu Tong B2B trading platform (www.yyjzt. com) and the "Zhiyao Tong" APP, linking upstream and downstream customer information systems, providing omnichannel, full category, full scene, "one-stop" digital distribution services and supply chain services. In the first half of 2022, the total revenue of Kyushu Tong's B2B e-commerce business was 7.228 billion yuan, accounting for 10.64% of the company's main business revenue. On the C-end, Kyushu Tong launched the "Power Health" medical service platform online, targeting C-end patients. The platform effectively integrates doctors, upstream industrial enterprises, supply chain platforms, medical institutions, and commercial insurance companies, forming a comprehensive internet health service platform that combines online and offline "medicine+medicine+insurance". At present, there are 112000 paying users on the C-end; Offline, accelerate retail terminal acceleration. Wandian Franchise has completed 8516 self operated and franchised pharmacies, and plans to achieve 10000 franchised pharmacies by the end of 2022. In the next three years, we will strive to achieve 30000 franchised pharmacies. This not only increases Kyushu Tong's market share in the off-site market, but also significantly increases the C-end service radius and capacity. In addition, Kyushu Tong has built a pharmaceutical supply chain platform that integrates warehousing, transportation, and distribution, and has established an industry specific "Bb/BC integrated" efficient supply chain logistics service model. At present, five BC integrated warehouses in Guangdong, Shanghai, Jiangsu, Hubei, and Hangzhou have been put into operation, with a daily acquisition rate of over 99%, greatly improving the efficiency of supply chain services and meeting the needs of different customers; The company has completed the logistics "Bb integration" transformation of four companies in Hubei, Chongqing, Shandong, and Henan, and has piloted the implementation of an integrated procurement and sales mechanism. It has established a "wholesale and retail integration" business execution mechanism with the retail business department of Haoyao Shi. 2022 is the starting year for Kyushu Tong to release the blueprint for digital transformation construction, with 16 digital transformation projects steadily advancing and achieving rich results; Among them, the "Zhiyao Tong" promotion project has launched external core functions such as actual reconciliation, return, payment, and incentive points. The first platform project has launched an electronic data exchange function and obtained authorization for third-party electronic signature services. The smart logistics project has completed the development of receiving appointment and intelligent outbound operation modules, and has been put into operation in the Chongqing company. The Kyushu Tong Financial Shared Cloud Platform has been selected for the "Typical Cases of Digital Transformation of Listed Companies" released by the China Association of Listed Companies. While focusing on development, Kyushu Tong actively practices the ESG development concept and fulfills corporate social responsibility.When floods are caused by rainstorm in Henan, Shanxi, Suizhou, Hubei and other places, we immediately organize rescue work and transport medicines and materials to support the disaster areas; When the epidemic spreads in multiple locations, we leverage the industry's scarce pharmaceutical supply chain service capabilities and actively participate in the fight against the epidemic and supply guarantee work; We have the courage to take on social responsibility, donate to multiple underdeveloped areas, implement industrial assistance, and strengthen our "hematopoietic" function. In 2021, the total value of our donations and supplies exceeded 200 million yuan. We have been awarded the title of "Humanity Enterprise" and "Advanced Party Organization of the Province" by Hubei Province. A new cycle of development in the pharmaceutical industry is approaching. Under the combined influence of the continuous promotion of medical insurance payment reform and internet medical policies by the country, technological development will continue to promote the continuous innovation of new models in the medical and health industry, and the industry reshuffle will accelerate. We will adhere to being a pioneer in the digitalization of pharmaceutical enterprises, based on the big health sunrise industries such as pharmaceutical circulation, logistics services, and medical health. We will unswervingly utilize the Internet and big data to better provide omnichannel, full variety, and full scenario services to upstream and downstream customers, create greater value for customers, and grow together with them. |
| Headquarter | Wuhan |
| Establish Date | 3/9/1999 |
| Listed Code | 600998.SH |
| Listed Date | 11/2/2010 |
| Chairman | Liu Changyun. |
| CEO | Hewei. |
| Website | www.jztey.com |
Buy Premium Now
$15/month billed now
View the full stack of insights immediately
Or 7 Days Free Charge for Trial
See feature available in the Trial and Premium
See our Solution and Servicetrial.solutionservice.trial
See our Uniquness and Value deliveringtrial.solutionservice.trial
